title: Anaerobic infections in cancer patients--a retrospective analysis of clindamycin, tinidazole, doxycycline, cefoxitin and lamoxactam.
abstract: The results of three consecutive clinical trials on the therapy of anaerobic infections in cancer patients have been compared. The success rate with lamoxactam (94%) (6000mg/d i.v.) was statistically different from that of doxycycline (63%) (300 mg/d per os). Clindamycin (1200 mg/d per os), clindamycin (2700 mg/d i.v.) and cefoxitin (6000 mg/d i.v.) resulted in a favourable outcome in approximately 80% of the patients. Mixed anaerobic infections had a similar response rate (80%). Even when the anaerobic pathogen was resistant to therapy, six of ten patients were cured. Surgical drainage played an important role, but was difficult to assess precisely.
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D002440:Cefoxitin / Q000627:therapeutic use; D002513:Cephamycins / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004318:Doxycycline / Q000627:therapeutic use; D004322:Drainage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009070:Moxalactam; D009369:Neoplasms / Q000150:complications* / Q000382:microbiology; D012189:Retrospective Studies; D014011:Tinidazole / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D002513:Cephamycins; D014011:Tinidazole; D002981:Clindamycin; D002440:Cefoxitin; D004318:Doxycycline; D009070:Moxalactam